Geleen, The Netherlands Temple Therapeutics BV (the “Company” or “Temple”)- September 10, 2018-Temple, a clinical stage biopharmaceutical company focused in developing therapeutics for fibrosis and oncology, announces the publication of groundbreaking mechanistic data for Evitar™ in Reproductive Sciences, a peer reviewed journal of the Society of Reproductive Investigations. Post-surgical adhesions are broadly recognized as the single greatest cause of surgical complications. Moreover, they have evaded effective intervention, until

Learn More

Temple Therapeutics B.V.'s vision is to “Challenge, Collaborate, Create” to bring innovative, impactful therapies which simplify and increase quality of life.  Achievement of which must be rooted in evidence, driven by science and the method of questioning. For 129 years, since Dembrowski’s first publication about post surgical adhesions, complete prevention is still elusive.  Advancement in science and those willing to challenge the paradigms led to the hypothesis that adhesion formation is the end result of an amplified fibrotic process.  Led by Temple's Chief Scientific Officer, Lynne Robertson, PhD.  and in collaboration with leading

Learn More

Women Focus On Short-Term Concerns Prior to Pelvic Surgery, Not Lasting Complications Red Bank, NJ – Although more than half of the country's women will have some type of pelvic surgery and are therefore at risk for surgical adhesions, a survey released this month by the not-for-profit National Women's Health Resource Center (NWHRC) finds that women are largely unaware of the health risks associated with

Learn More

MeEt Us

View our upcoming events

View All Events